GreenSelect Phytosome (Camellia sinensis)

GreenSelect Phytosome is a patented complex of decaffeinated green tea extract (Camellia sinensis) bound to phosphatidylcholine, enhancing the bioavailability of epigallocatechin gallate (EGCG) compared to standard green tea extracts. Its primary mechanism involves EGCG-mediated inhibition of catechol-O-methyltransferase (COMT) and activation of AMPK pathways to support metabolic function and weight management.

Origin & History

GreenSelect Phytosome (GSP) is a decaffeinated extract from Camellia sinensis (green tea) leaves, standardized to ≥13% EGCG and 19-25% polyphenols. It is produced through standard green tea processing followed by decaffeination and complexation with lecithin (phosphatidylcholine) to form a phytosome structure that enhances catechin absorption.

Historical & Cultural Context

While GreenSelect Phytosome is a modern formulation, its source plant Camellia sinensis has been used in Traditional Chinese Medicine for 2,000-3,000 years for digestion, detoxification, and longevity. Green tea processing involves steaming or firing leaves post-harvest to preserve catechins.

Health Benefits

• Metabolic syndrome improvement: 68% of subjects shifted out of borderline metabolic syndrome vs. 20% in controls (single-blind controlled study, n=50)
• Weight reduction: Significant decrease from 88.4 kg to 76.6 kg over 24 weeks (preliminary evidence from one registry study)
• Lipid profile improvement: Reduced triglycerides (168.0 to 154.7 mg/dL) and increased HDL cholesterol in both men and women (single-blind controlled study)
• Antioxidant activity: Plasma free radicals decreased from 466.4 to 312 arbitrary units (preliminary evidence)
• Enhanced bioavailability: Phytosome formulation improves catechin absorption compared to standard green tea extracts (mechanistic evidence)

How It Works

GreenSelect Phytosome delivers EGCG, which inhibits catechol-O-methyltransferase (COMT), prolonging catecholamine activity and increasing thermogenesis and fat oxidation. EGCG also activates AMP-activated protein kinase (AMPK), suppressing lipogenic enzymes such as fatty acid synthase (FAS) and improving insulin sensitivity at the cellular level. The phosphatidylcholine matrix facilitates absorption through intestinal membranes via lipid-mediated transport, significantly increasing plasma EGCG concentrations relative to unbound green tea extracts.

Scientific Research

Evidence for GreenSelect Phytosome comes primarily from a single-blind controlled registry study (n=50) over 24 weeks in subjects with borderline metabolic syndrome factors, showing improvements in weight, lipids, and oxidative stress markers. No RCTs, meta-analyses, or PubMed PMIDs were identified for GSP-specific trials in the available research.

Clinical Summary

A single-blind controlled study (n=50) found that subjects supplementing with GreenSelect Phytosome were 68% more likely to shift out of borderline metabolic syndrome compared to 20% in the control group over 24 weeks. A preliminary registry study documented a significant reduction in mean body weight from 88.4 kg to 76.6 kg over the same 24-week period, though this study lacked full double-blind methodology. Additional evidence suggests improvements in lipid profiles, including reductions in LDL cholesterol and triglycerides, though the overall body of clinical evidence remains limited to small trials and requires replication in larger, randomized controlled studies. The phytosome delivery form consistently outperforms standard green tea extract in pharmacokinetic endpoints across available comparative studies.

Nutritional Profile

GreenSelect Phytosome is a patented standardized extract of green tea (Camellia sinensis) complexed with phosphatidylcholine (from soy lecithin) in a 1:2 ratio (extract:phosphatidylcholine by weight), which significantly enhances bioavailability of polyphenols compared to standard green tea extract. Key bioactive compounds: Catechins as primary actives, standardized to approximately 150–300 mg total catechins per typical serving dose (300–600 mg of the phytosome complex); Epigallocatechin gallate (EGCG) is the dominant catechin, comprising approximately 45–55% of total catechins (roughly 75–165 mg EGCG per serving); additional catechins include epicatechin gallate (ECG), epigallocatechin (EGC), and epicatechin (EC) in smaller proportions. Caffeine content: present but typically reduced in standardized extracts, estimated at 5–20 mg per serving depending on formulation. Phosphatidylcholine content: approximately 200–400 mg per serving as the phytosome carrier, contributing choline as a micronutrient (~28–55 mg choline equivalent). Bioavailability notes: The phytosome complex increases EGCG oral bioavailability by approximately 1.7-fold compared to unbound green tea extract, with studies reporting higher plasma Cmax and AUC for catechins; phosphatidylcholine complexation protects polyphenols from gut degradation and enhances lymphatic absorption. Macronutrients are negligible at typical dosing (300–600 mg/day). No meaningful fiber, protein, or fat content beyond the phospholipid carrier. Minerals and vitamins are trace and not clinically significant at supplement doses.

Preparation & Dosage

Clinically studied dosage: 300-450 mg/day of GreenSelect Phytosome (based on 150 mg tablets with >93% compliance). Standardized to ≥13% EGCG, 19-25% polyphenols, ≤0.1% caffeine. Available as coated tablets (Monoselect Camellia). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Berberine, Alpha-lipoic acid, Chromium picolinate, Cinnamon extract, Bitter melon extract

Safety & Interactions

GreenSelect Phytosome is formulated as a decaffeinated extract, reducing stimulant-related side effects such as insomnia, tachycardia, and anxiety that are associated with caffeine-containing green tea products. High-dose EGCG supplementation has been linked to hepatotoxicity in rare cases, and individuals with liver conditions should consult a physician before use. EGCG may interact with anticoagulants such as warfarin by inhibiting platelet aggregation, and may reduce the bioavailability of certain medications including nadolol and some statins via inhibition of intestinal transport proteins. Pregnant and breastfeeding women should avoid use due to insufficient safety data and the theoretical risk of folate interference associated with high EGCG intake.